Elevance Health, US0367521038

Elevance Health stock gets 490 US dollar target from Mizuho

Published on 11/17/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health stock draws a Buy rating from Mizuho Securities. The analyst set a new target as investors assess the insurer's margin recovery.

Mizuho keeps focus on Elevance

  • Mizuho Securities maintained a Buy rating for Elevance Health and set a new price target.
  • Elevance's latest quarterly revenue and net income exceeded the prior-year figures cited in the report.
  • Medicaid margins, Medicare Advantage profitability and 2027 earnings growth remain central investor issues.
Elevance Health, US0367521038, Illustration mit AI erstellt.

On November 16, 2026, Mizuho Securities analyst Ann Hynes maintained a Buy rating on Elevance Health and set a 490 US dollar price target, according to Markets Insider, which attributed the item to TipRanks.

Elevance Health stock traded at 395.25 euros on Lang & Schwarz at 13:43 CET on Tuesday, November 17, 2026. The quote provides a current European trading reference while the Mizuho target is denominated in US dollars and relates to the New York-listed shares.

Analyst view follows stronger quarter

The report placed the rating against Elevance's latest quarterly performance. Revenue for the quarter ended September 30 was 51.43 billion US dollars, compared with 50.71 billion US dollars a year earlier. Net income reached 1.37 billion US dollars, up from 1.19 billion US dollars in the prior-year quarter.

For investors, the rating keeps attention on whether the insurer can convert improved operating execution into durable earnings growth. Medicaid profitability is expected to improve as reimbursement rates catch up with medical-cost trends, although the pace of recovery depends on state rate actions and membership developments. Medicare Advantage margins and the performance of Carelon also remain important to the earnings path.

Elevance had raised its 2026 outlook with its third-quarter results. The company has also outlined a path toward at least 12 percent adjusted earnings-per-share growth in 2027, with margin recovery and expansion in pharmacy and clinical services supporting that ambition. Those factors frame the relevance of the Mizuho target, while medical-cost inflation and enrollment trends remain material risks.

Analyst targets are estimates rather than company commitments, and the Mizuho rating does not change Elevance's operating outlook by itself. The next material focus for shareholders is the insurer's execution against its 2026 guidance and the assumptions underpinning its 2027 margin recovery.

Elevance Health stock facts

  • Company: Elevance Health Inc.
  • ISIN: US0367521038
  • Ticker: ELV
  • Primary listing: New York Stock Exchange
  • Sector: Healthcare
  • Lang & Schwarz quote: 395.25 euros at 13:43 CET on November 17, 2026

Broader US equity sentiment can be followed in the S&P 500.

More news and analyses on Elevance Health stock

Disclaimer...
en | US0367521038 | ELEVANCE HEALTH | boerse | 70526944 | bgmi